Ugradar S - Search Results

1

Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression.

Ugradar S, Shi L, Wang Y, Mester T, Yang H, Douglas RS. Ugradar S, et al. Eye (Lond). 2021 Sep;35(9):2607-2612. doi: 10.1038/s41433-020-01297-w. Epub 2020 Nov 21. Eye (Lond). 2021. PMID: 33221815 Free PMC article.

2

Noninflammatory Thyroid Eye Disease.

Ugradar S, Rootman DB. Ugradar S, et al. Ophthalmic Plast Reconstr Surg. 2019 Sep/Oct;35(5):461-464. doi: 10.1097/IOP.0000000000001087. Ophthalmic Plast Reconstr Surg. 2019. PMID: 29465483

3

Measurement of Medial Wall Bowing and Clinical Associations in Thyroid Eye Disease.

Bokman CL, Ugradar S, Rootman DB. Bokman CL, et al. Among authors: ugradar s. Ophthalmic Plast Reconstr Surg. 2018 Nov/Dec;34(6):557-559. doi: 10.1097/IOP.0000000000001098. Ophthalmic Plast Reconstr Surg. 2018. PMID: 29505466

4

A novel technique for the measurement of eyelid contour to compare outcomes following Muller's muscle-conjunctival resection and external levator resection surgery.

Danesh J, Ugradar S, Goldberg R, Rootman DB. Danesh J, et al. Among authors: ugradar s. Eye (Lond). 2018 Sep;32(9):1493-1497. doi: 10.1038/s41433-018-0105-4. Epub 2018 May 24. Eye (Lond). 2018. PMID: 29799019 Free PMC article.

5

Bony Orbital Volume Expansion in Thyroid Eye Disease.

Ugradar S, Goldberg RA, Rootman DB. Ugradar S, et al. Ophthalmic Plast Reconstr Surg. 2019 Sep/Oct;35(5):434-437. doi: 10.1097/IOP.0000000000001292. Ophthalmic Plast Reconstr Surg. 2019. PMID: 30550499

6

Orbital fat expansion in thyroid eye disease is related to age.

Ugradar S, Rootman DB. Ugradar S, et al. Eur J Ophthalmol. 2020 Sep;30(5):1004-1007. doi: 10.1177/1120672119852322. Epub 2019 May 30. Eur J Ophthalmol. 2020. PMID: 31144509

7

Facial numbness in the ophthalmology clinic. A portentous sign.

Ugradar S, Bonelli L, Rootman D. Ugradar S, et al. Eye (Lond). 2020 Apr;34(4):663-668. doi: 10.1038/s41433-019-0565-1. Epub 2019 Aug 30. Eye (Lond). 2020. PMID: 31471563 Free PMC article.

8

Quantification of optic nerve length and tortuosity in thyroid eye disease.

Ugradar S, Rootman DB. Ugradar S, et al. Can J Ophthalmol. 2019 Oct;54(5):611-614. doi: 10.1016/j.jcjo.2019.01.007. Epub 2019 Apr 2. Can J Ophthalmol. 2019. PMID: 31564353

9

Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease.

Jain AP, Gellada N, Ugradar S, Kumar A, Kahaly G, Douglas R. Jain AP, et al. Among authors: ugradar s. Br J Ophthalmol. 2022 Feb;106(2):165-171. doi: 10.1136/bjophthalmol-2020-317806. Epub 2020 Nov 10. Br J Ophthalmol. 2022. PMID: 33172865

10

Improvement of asymmetric thyroid eye disease with teprotumumab.

Ugradar S, Wang Y, Mester T, Kahaly GJ, Douglas R. Ugradar S, et al. Br J Ophthalmol. 2022 Jun;106(6):755-759. doi: 10.1136/bjophthalmol-2020-318314. Epub 2021 Feb 12. Br J Ophthalmol. 2022. PMID: 33579690 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

70 results

Search Page

Filters